Open AccessMYCOPHENOLATE MOFETIL: A PROMISING NEW IMMUNOSUPPRESSANT THAT DOES NOT CAUSE BONE LOSS IN THE RAT1,2
Author(s) -
Imara Dissanayake,
Grant R. Goodman,
Andrew R. Bowman,
Yang Ma,
S Pun,
W.S.S. Jee,
Sol Epstein
Publication year - 1998
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199801270-00025
Subject(s) - mycophenolate , osteocalcin , osteopenia , medicine , osteoid , endocrinology , bone histomorphometry , bone remodeling , urology , bone mineral , chemistry , osteoporosis , trabecular bone , transplantation , alkaline phosphatase , biochemistry , enzyme
Posttransplantation bone disease is a well-described phenomenon; among its etiology is immunosuppressant-induced bone disease. Mycophenolate mofetil (MMF) has emerged as a promising new immunosuppressant. Our study was designed to investigate the effect of MMF on in vivo bone mineral metabolism.